Apixaban-induced hepatotoxicity

International Journal of Cardiology

Volumn 204, Issue , 2016, Pages 4-5

  Cordeanu, Mihaela ^a   Lambert, Aude ^b   Gaertner, Sébastien ^a   Nouri, Salah ^a   Mirea, Corina ^a   Alt Tebacher, Martine ^b   Stephan, Dominique ^a,b  

^a Strasbourg Regional University Hospital   (France)

^b Regional Pharmacovigilance Centre   (France)

Author keywords

Apixaban; Atrial fibrillation; Direct oral anticoagulant; Drug induced liver injury; Hepatotoxicity

Indexed keywords

ALANINE AMINOTRANSFERASE; ALKALINE PHOSPHATASE; AMLODIPINE; ANTIVITAMIN K; APIXABAN; ASPARTATE AMINOTRANSFERASE; BILIRUBIN; BISOPROLOL; BROMAZEPAM; FLECAINIDE; GAMMA GLUTAMYLTRANSFERASE; LOW MOLECULAR WEIGHT HEPARIN; SULPIRIDE; BLOOD CLOTTING FACTOR 10A INHIBITOR; PYRAZOLE DERIVATIVE; PYRIDONE DERIVATIVE;

AGED; ARTICLE; CASE REPORT; CHADS2 SCORE; FEMALE; GLOMERULUS FILTRATION RATE; HUMAN; HYPERTENSION; LIVER CELL DAMAGE; LIVER TOXICITY; PACEMAKER IMPLANTATION; PAROXYSMAL ATRIAL FIBRILLATION; PRIORITY JOURNAL; SINUS NODE DISEASE; VISUAL ANALOG SCALE; DRUG-INDUCED LIVER INJURY; ENZYMOLOGY;

AGED; DRUG-INDUCED LIVER INJURY; FACTOR XA INHIBITORS; FEMALE; HUMANS; PYRAZOLES; PYRIDONES;

EID: 84955271496     PISSN: 01675273     EISSN: 18741754     Source Type: Journal    
DOI: 10.1016/j.ijcard.2015.11.147     Document Type: Article

References (9)

1. M. Keisu, and T.B. Andersson Drug-induced liver injury in humans: the case of ximelagatran Handb. Exp. Pharmacol. 196 2010 407 418
2. D. Caldeira, M. Barra, A.T. Santos, and et al. Risk of drug-induced liver injury with the new oral anticoagulants: systematic review and meta-analysis Heart 100 7 2014 550 556
3. S. Russmann, D.F. Niedrig, M. Budmiger, and et al. Rivaroxaban postmarketing risk of liver injury J. Hepatol. 61 2 2014 Aug 293 300
4. E. Liakoni, A.E. Rätz Bravo, L. Terracciano, M. Heim, and S. Krähenbühl Symptomatic hepatocellular liver injury with hyperbilirubinemia in two patients treated with rivaroxaban JAMA Intern. Med. 174 10 2014 Oct 1683 1686
5. A. Lambert, M. Cordeanu, S. Gaertner, S. Nouri, M. Alt, and D. Stephan Rivaroxaban-induced liver injury: results from a venous thromboembolism registry Int. J. Cardiol. 191 2015 265 266
6. E. Liakoni, A.E. Rätz Bravo, and S. Krähenbühl Hepatotoxicity of New Oral Anticoagulants (NOACs) Drug Saf. 38 8 2015 711 720
7. E. Raschi, E. Poluzzi, A. Koci, and et al. Liver injury with novel oral anticoagulants: assessing post-marketing reports in the US Food and Drug Administration adverse event reporting system Br. J. Clin. Pharmacol. 80 2 2015 285 293
8. Eudravigilance, Eliquis, July 2015.
9. C.E. Mahan Practical aspects of treatment with target specific anticoagulants: initiation, payment and current market, transitions, and venous thromboembolism treatment J. Thromb. Thrombolysis 39 3 2015 295 303